SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-030494
Filing Date
2024-03-04
Accepted
2024-03-04 16:10:56
Documents
16
Period of Report
2024-03-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247839d1_8k.htm   iXBRL 8-K 25275
2 EXHIBIT 99.1 tm247839d1_ex99-1.htm EX-99.1 99420
6 GRAPHIC tm247839d1_ex99-1img01.jpg GRAPHIC 4938
  Complete submission text file 0001104659-24-030494.txt   318006

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cara-20240304.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cara-20240304_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cara-20240304_pre.xml EX-101.PRE 22375
17 EXTRACTED XBRL INSTANCE DOCUMENT tm247839d1_8k_htm.xml XML 3615
Mailing Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901
Business Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36279 | Film No.: 24715069
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)